A Phase 3 interventional study of Levomilnacipran ER and Fluoxetine in Major Depressive Disorder, sponsored by Allergan. Completed at 51 sites in United States. Open to participants aged 7 Years to 17 Years. Per ClinicalTrials.gov, last updated 2022-03-25.
Sponsored by Allergan (part of AbbVie) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies testing levomilnacipran in Depressive Disorder, Major — none open to participants now, none under way, none of them phase 3. Levomilnacipran · Depressive Disorder, Major.
Among the 14 studies testing levomilnacipran in Depressive Disorder, Major, this one is the 7th largest by enrollment, is the only one that started in 2018, is one of 10 in phase 3, and was the 13th registered.
3,048 studies on the registry are indexed under Depressive Disorder, Major; 593 are open to participants now.
Browse Depressive Disorder, Major studies →None of the 14 studies testing levomilnacipran in Depressive Disorder, Major is open now. The open studies under Depressive Disorder, Major, anywhere →
Levomilnacipran: first FDA approval 2013 (FETZIMA). What it is approved for, and how studies give it, is on its page →
Of the 414 Depressive Disorder, Major studies recruiting now, 93 (22%) set no upper age limit and 294 (71%) stop at 75 or younger; 55 take children under 18; 99 take healthy volunteers.
This study: 7 Years to 17 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
First in 2009; this study’s year is marked. 1 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 501 is above the median of 80 across 2,534 interventional studies indexed under Depressive Disorder, Major.
Median enrollment 472 across the 14 interventional studies. Of the 14 that completed or were terminated, 12 (86%) have results posted.
This tab as a report to print or save as PDF → With an account.
11 of 14 have an industry lead sponsor. The 6 most frequent:
This study is registered under Allergan, one of the names counted as AbbVie. Under that name alone:
Allergan is the lead sponsor of 505 studies on the registry; none are open to participants now.
Of its 93 completed or terminated interventional studies of FDA-regulated products, 91 (98%) have results posted.
53 studies in Depressive Disorder, Major by AbbVie: 1 open now, 1 under way, none of them phase 3. Of 50 finished, 37 (74%) have results posted.
Among the 53 studies in Depressive Disorder, Major by AbbVie, this one is the 22nd largest by enrollment, is one of 7 that started in 2018, is one of 31 in phase 3, and was the 43rd registered.
AbbVie’s Depressive Disorder, Major studies by the year they started, since 2005.
None of the studies under way reaches primary completion within a year.
Among the 14 studies testing levomilnacipran in Depressive Disorder, Major, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among AbbVie’s 53 in Depressive Disorder, Major:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The objective of this study is to evaluate the efficacy, safety, and tolerability of levomilnacipran compared with placebo in pediatric outpatients (7-17 years) with major depressive disorder (MDD).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Suicide risk as determined by meeting either of the following criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Levomilnacipran extended release (ER) capsules, orally, 10 milligram per day (mg/day) on Days 1 to 3, 20 mg/day on Days 4 to 7, and 40 mg/day from Week 2 through Week 8 of the Double-blind Treatment Period followed by levomilnacipran ER 40 mg/day on Days 1 and 2, and then 20 mg/day from Day 3 through Day 7 in the Down-taper Period. Based on therapeutic response and tolerability, an additional dose increase to 80 mg/day was permitted at Week 3 of the Double-blind Treatment Period.
Drug: Levomilnacipran ER
Fluoxetine capsule, orally, 10 mg/day at Week 1, and 20 mg/day from Week 2 through Week 8 of the Double-blind Treatment Period followed by fluoxetine 10 mg/day from Day 1 through Day 7 of the Down-taper Period.
Drug: Fluoxetine
Matching placebo capsules once daily through 8 weeks in the Double-blind Treatment Period and Days 1 through 7 in the Down-taper Period.
Drug: Placebo
Levomilnacipran extended-release oral capsules
Fluoxetine oral capsules
Matching placebo oral capsules
Change From Baseline in Children's Depression Rating Scale- Revised (CDRS-R)
The CDRS-R is a semi-structured, clinician-rated instrument designed for use with children and adolescents between the ages of 6-17 years. It contains 17 ordinally-scaled items that evaluate the presence and severity of symptoms commonly associated with childhood depression and is scored on a 1-to-5- or 1-to-7-point scale. Rating of 1 indicates normal function. The CDRS-R total score ranges from 17 to 113; higher score indicates more severe depression. A negative change from Baseline indicates improvement. Mixed Model for Repeated Measures (MMRM) was used for analysis.
Time frame: Baseline (Week 0) to Week 8
Change From Baseline in Clinical Global Impression-Severity (CGI-S) Scale
The CGI-S is a clinician-rated scale used to rate the severity of the participant's current state of mental illness compared with MDD population. The participant was rated on a scale from 1 to 7, where 1=normal, not at all ill and 7=among the most extremely ill participants. Higher score indicates worsening of mental illness. A negative change from Baseline indicates improvement. MMRM was used for analysis.
Time frame: Baseline (Week 0) to Week 8
| Milestone | Placebo | Levomilnacipran ER 40-80 mg/Day | Fluoxetine 20 mg/Day |
|---|---|---|---|
| Started | 164 | 169 | 168 |
| Safety population | 160 | 166 | 166 |
| Completed | 146 | 146 | 144 |
| Not completed | 18 | 23 | 24 |
| Withdrew: Adverse event | 1 | 2 | 5 |
| Withdrew: Lack of efficacy | 0 | 1 | 0 |
| Withdrew: Withdrawal by subject | 7 | 10 | 9 |
| Withdrew: Lost to follow-up | 7 | 7 | 6 |
| Withdrew: Protocol deviation | 1 | 1 | 1 |
| Withdrew: Non-compliance with study drug | 1 | 1 | 1 |
| Withdrew: Reason not specified | 1 | 1 | 2 |
| Milestone | Placebo | Levomilnacipran ER 40-80 mg/Day | Fluoxetine 20 mg/Day |
|---|---|---|---|
| Started | 140 | 141 | 140 |
| Completed | 140 | 139 | 138 |
| Not completed | 0 | 2 | 2 |
| Withdrew: Lost to follow-up | 0 | 1 | 1 |
| Withdrew: Withdrawal by subject | 0 | 1 | 1 |
The CDRS-R is a semi-structured, clinician-rated instrument designed for use with children and adolescents between the ages of 6-17 years. It contains 17 ordinally-scaled items that evaluate the presence and severity of symptoms commonly associated with childhood depression and is scored on a 1-to-5- or 1-to-7-point scale. Rating of 1 indicates normal function. The CDRS-R total score ranges from 17 to 113; higher score indicates more severe depression. A negative change from Baseline indicates improvement. Mixed Model for Repeated Measures (MMRM) was used for analysis.
| score on a scale | Placebo | Levomilnacipran ER 40-80 mg/Day | Fluoxetine 20 mg/Day |
|---|---|---|---|
| Change From Baseline in Children's Depression Rating Scale- Revised (CDRS-R) | -21.3 ± 1.01 | -23.0 ± 1.01 | -23.1 ± 1.01 |
The CGI-S is a clinician-rated scale used to rate the severity of the participant's current state of mental illness compared with MDD population. The participant was rated on a scale from 1 to 7, where 1=normal, not at all ill and 7=among the most extremely ill participants. Higher score indicates worsening of mental illness. A negative change from Baseline indicates improvement. MMRM was used for analysis.
| score on a scale | Placebo | Levomilnacipran ER 40-80 mg/Day | Fluoxetine 20 mg/Day |
|---|---|---|---|
| Change From Baseline in Clinical Global Impression-Severity (CGI-S) Scale | -1.5 ± 0.10 | -1.6 ± 0.10 | -1.7 ± 0.10 |
Collected over Up to approximately 9 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo (Double-blind Treatment Period) | 0/164 (0%) | 1/160 (0.6%) | 32/160 (20%) |
| Levomilnacipran ER 40-80 mg/Day (Double-blind Treatment Period) | 0/169 (0%) | 1/166 (0.6%) | 44/166 (26.5%) |
| Fluoxetine 20 mg/Day (Double-blind Treatment Period) | 0/168 (0%) | 4/166 (2.4%) | 37/166 (22.3%) |
| Placebo (Down-taper Period) | 0/160 (0%) | 1/160 (0.6%) | 3/160 (1.9%) |
| Levomilnacipran ER 40-80 mg/Day (Down-taper Period) | 0/166 (0%) | 0/166 (0%) | 3/166 (1.8%) |
| Fluoxetine 20 mg/Day (Down-taper Period) | 0/166 (0%) | 0/166 (0%) | 1/166 (0.6%) |
| Event | Placebo (Double-blind Treatment Period) | Levomilnacipran ER 40-80 mg/Day (Double-blind Treatment Period) | Fluoxetine 20 mg/Day (Double-blind Treatment Period) | Placebo (Down-taper Period) | Levomilnacipran ER 40-80 mg/Day (Down-taper Period) | Fluoxetine 20 mg/Day (Down-taper Period) |
|---|---|---|---|---|---|---|
| Suicidal ideationPsychiatric disorders | 0/160 | 0/166 | 2/166 | 0/160 | 0/166 | 0/166 |
| Major depressionPsychiatric disorders | 0/160 | 1/166 | 0/166 | 1/160 | 0/166 | 0/166 |
| Suicide attemptPsychiatric disorders | 1/160 | 0/166 | 0/166 | 0/160 | 0/166 | 0/166 |
| Bipolar I disorderPsychiatric disorders | 0/160 | 0/166 | 1/166 | 0/160 | 0/166 | 0/166 |
| Intentional self-injuryPsychiatric disorders | 0/160 | 0/166 | 1/166 | 0/160 | 0/166 | 0/166 |
| Event | Placebo (Double-blind Treatment Period) | Levomilnacipran ER 40-80 mg/Day (Double-blind Treatment Period) | Fluoxetine 20 mg/Day (Double-blind Treatment Period) | Placebo (Down-taper Period) | Levomilnacipran ER 40-80 mg/Day (Down-taper Period) | Fluoxetine 20 mg/Day (Down-taper Period) |
|---|---|---|---|---|---|---|
| HeadacheNervous system disorders | 19/160 | 21/166 | 19/166 | 2/160 | 2/166 | 0/166 |
| NauseaGastrointestinal disorders | 6/160 | 16/166 | 5/166 | 1/160 | 1/166 | 1/166 |
| Decreased appetiteMetabolism and nutrition disorders | 5/160 | 11/166 | 12/166 | 0/160 | 0/166 | 0/166 |
| TachycardiaCardiac disorders | 0/160 | 10/166 | 2/166 | 0/160 | 0/166 | 0/166 |
| InsomniaPsychiatric disorders | 9/160 | 2/166 | 5/166 | 0/160 | 1/166 | 0/166 |
Safety Population included all participants in the Randomized Population who received at least 1 dose of double-blind investigational product.
| Age, Continuous(years) | Placebo | Levomilnacipran ER 40-80 mg/Day | Fluoxetine 20 mg/Day | Total |
|---|---|---|---|---|
| Mean | 13.6 ± 2.48 | 13.7 ± 2.56 | 13.3 ± 2.66 | 13.5 ± 2.57 |
| Sex: Female, Male(Participants) | Placebo | Levomilnacipran ER 40-80 mg/Day | Fluoxetine 20 mg/Day | Total |
|---|---|---|---|---|
| Female | 114 | 99 | 105 | 318 |
| Male | 46 | 67 | 61 | 174 |
| Ethnicity (NIH/OMB)(Participants) | Placebo | Levomilnacipran ER 40-80 mg/Day | Fluoxetine 20 mg/Day | Total |
|---|---|---|---|---|
| Hispanic or Latino | 45 | 40 | 40 | 125 |
| Not Hispanic or Latino | 115 | 126 | 126 | 367 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Placebo | Levomilnacipran ER 40-80 mg/Day | Fluoxetine 20 mg/Day | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 1 | 0 | 1 | 2 |
| Asian | 2 | 4 | 0 | 6 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 54 | 61 | 58 | 173 |
| White | 102 | 96 | 104 | 302 |
| More than one race | 1 | 5 | 3 | 9 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Children's Depression Rating Scale-Revised (CDRS-R) Total Score(score on a scale) | Placebo | Levomilnacipran ER 40-80 mg/Day | Fluoxetine 20 mg/Day | Total |
|---|---|---|---|---|
| Mean | 60.8 ± 8.99 | 60.8 ± 9.17 | 60.9 ± 9.88 | 60.8 ± 9.34 |
| Clinical Global Impression-Severity (CGI-S) Scale(score on a scale) | Placebo | Levomilnacipran ER 40-80 mg/Day | Fluoxetine 20 mg/Day | Total |
|---|---|---|---|---|
| Mean | 4.8 ± 0.64 | 4.7 ± 0.64 | 4.8 ± 0.60 | 4.8 ± 0.63 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols and clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: For details on when studies are available for sharing, please refer to the link below.
Access criteria: Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous, independent scientific research, and will be provided following review and approval of a research proposal and Statistical Analysis Plan (SAP) and execution of a Data Use Agreement (DUA). For more information on the process, or to submit a request, visit the following link.
Data sharing details ↗ · vivli.org
Ran from Jul 2018 to primary completion in Mar 2021, 31 months.
Results were first posted in Mar 2022, 1 year after primary completion.
Of 95 industry-sponsored phase 3 interventional studies under Depressive Disorder, Major, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 33. This study's 31 months is above that.
Counting every sponsor, half of 124 studies reached it within 27 months; a quarter within 21 and three quarters within 36.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Levomilnacipran